HealthcareServices

Immunoglobulin A IgA Vasculitis Market Forecast 2026: Where the Industry Is Headed

February 25, 2026February 26, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the immunoglobulin a iga vasculitis market from 2026–2035 with trusted insights from The Business Research Company

What upper market value could the Immunoglobulin A IgA Vasculitis Market reach by 2030 starting from 2026 levels?

The immunoglobulin a iga vasculitis market has experienced robust expansion in recent years. Projections indicate it will expand from $1.63 billion in 2025 to $1.74 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.5%. Historically, this growth can be ascribed to several factors, including an enhanced clinical comprehension of IgA-mediated autoimmune disorders, a rise in the diagnosis of pediatric vasculitis cases, more widespread application of corticosteroids and immunosuppressants, the proliferation of hospital-based autoimmune care services, and the broadening of nephrology clinical expertise.

The market for immunoglobulin A (IgA) vasculitis is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach a valuation of $2.21 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.2%. This projected growth is attributable to several factors, including heightened research into new immunomodulatory drugs, the increasing embrace of personalized autoimmune treatments, a greater emphasis on long-term kidney protection, the broadening of biologic treatment options, and advancements in diagnostic imaging and biopsy methods. Key trends anticipated during the forecast period involve an increased focus on prompt and precise disease diagnosis, the rising use of targeted immunosuppressive treatments, the expanding application of biomarker-driven disease monitoring, the growth of personalized therapeutic strategies, and an intensified concentration on managing renal outcomes.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24567&type=smp

Which Drivers Are Influencing Long-Term Growth In The Immunoglobulin A IgA Vasculitis Market?

An increase in the prevalence of autoimmune diseases is projected to fuel the expansion of the immunoglobulin A (IgA) vasculitis market moving forward. Autoimmune diseases are conditions where the body’s immune system incorrectly attacks its own healthy cells, tissues, or organs instead of safeguarding the body from infections and foreign substances. The growing incidence of autoimmune disorders is primarily attributed to increased exposure to pollutants, which can disrupt immune regulation and trigger abnormal responses. Immunoglobulin A (IgA) vasculitis assists in addressing autoimmune diseases by initiating an immune response that results in inflammation within small blood vessels, thereby aiding in the understanding and potential treatment of various autoimmune conditions. For example, in February 2024, according to the Vasculitis Foundation, a US-based non-profit organization, the annual incidence of IgA vasculitis in U.S. adults is approximately 2 cases per 100,000, although global rates vary considerably, ranging from roughly 60 to 550 cases per million. Consequently, the rising occurrence of autoimmune diseases is driving the growth of the immunoglobulin A (IgA) vasculitis market. The increasing focus on targeted therapies is anticipated to stimulate the growth of immunoglobulin A (IgA) vasculitis. Targeted therapies are treatments that specifically identify and inhibit molecular abnormalities in cancer or other diseases to enhance treatment precision and minimize harm to healthy cells. This growing emphasis on targeted therapies is primarily driven by advancements in precision medicine, which facilitates personalized, more effective treatments based on individual genetic profiles. Targeted therapies aid immunoglobulin A (IgA) vasculitis treatment by concentrating on specific immune pathways, thereby minimizing systemic side effects. They improve disease management by reducing inflammation and preventing organ damage, which enhances patient outcomes and quality of life. For instance, in December 2024, as reported by the American Society of Gene and Cell Therapy (ASGCT), a US-based non-profit medical and scientific organization, the Food and Drug Administration (FDA) approved six gene therapy products in 2023, an increase from five approvals in 2022. Therefore, the rising focus on targeted therapies is propelling the growth of the immunoglobulin A (IgA) vasculitis market.

Which Segments Are Driving Activity In The Immunoglobulin A IgA Vasculitis Market?

The immunoglobulin a iga vasculitis market covered in this report is segmented –

1) By Treatment Type: Medications, Plasma Exchange, Supportive Care, Immunosuppressive Therapy

2) By Diagnosis Method: Blood Tests, Urinalysis, Imaging Studies, Biopsy

3) By Route Of Administration: Oral, Injectables

4) By End User: Hospitals, Specialty Clinics, Homecare Settings

Subsegments:

1) By Medications: Corticosteroids, Immunosuppressants, Cyclophosphamide, Azathioprine, Mycophenolate Mofetil

2) By Plasma Exchange: Therapeutic Plasma Exchange, Plasma Filtration

3) By Supportive Care: Pain Management, Kidney Function Support, Blood Pressure Management

4) By Immunosuppressive Therapy: Methotrexate, Rituximab

How Are New Market Trends Shaping The Landscape Of The Immunoglobulin A IgA Vasculitis Market?

Companies operating in the immunoglobulin A (IgA) vasculitis market are concentrating on creating innovative therapies, including targeted biologics and immunomodulators, to alleviate inflammation and avert renal complications. These advanced therapies modulate specific immune pathways to lessen inflammation and prevent immune-mediated damage in IgA vasculitis. For instance, in April 2025, Novartis AG, a Switzerland-based pharmaceutical company, obtained approval from the U.S. Food and Drug Administration (FDA) for Vanrafia (atrasentan) for the treatment of primary immunoglobulin A nephropathy (IgAN). Vanrafia is an oral, once-daily, selective endothelin A receptor antagonist designed to reduce proteinuria in adults with primary IgAN who are at risk of rapid disease progression. It can be integrated into existing supportive care regimens without needing a risk evaluation and mitigation strategy (REMS).

Which Key Players Are Driving Competition In The Immunoglobulin A IgA Vasculitis Market?

Major companies operating in the immunoglobulin a iga vasculitis market are Pfizer Inc, F. Hoffmann-La Roche Ltd, Novartis AG, Takeda Pharmaceutical Company Limited, Amgen Inc, Intas Pharmaceuticals Ltd, Zydus Lifesciences Limited, Biogen Inc, Chugai Pharmaceutical Co Ltd, CSL Behring, AbbVie Inc, Johnson & Johnson, Bristol-Myers Squibb Company, UCB SA, Sanofi, GSK plc, Astellas Pharma Inc, Teva Pharmaceuticals USA Inc, Chinook Therapeutics, Guangdong Hengrui Pharmaceutical Co Ltd, Visterra Inc, Selecta Biosciences, Jiangsu HengRui Medicine Co Ltd, Travere Therapeutics Inc, Everest Medicines Ltd

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/immunoglobulin-a-iga-vasculitis-global-market-report

Which Region Currently Holds The Largest Share Of The Immunoglobulin A IgA Vasculitis Market?

North America was the largest region in the immunoglobulin A (IgA) vasculitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunoglobulin a iga vasculitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Immunoglobulin A IgA Vasculitis Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24567&type=smp

Browse Through More Reports Similar to the Global Immunoglobulin A IgA Vasculitis Market 2026, By The Business Research Company

Intravenous Immunoglobulin Market Report 2026

https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report

Immunodiagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunodiagnostics-global-market-report

Veterinary Autoimmune Disease Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-autoimmune-disease-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795